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Abstract
Phosphatidylinositol 3-kinase (PI 3-kinase) plays a role in late stages of endocytosis as well as in cellular proliferation and
transformation. The SH3 domain of its regulatory p85 subunit stimulates the GTPase activity of dynamin in vitro. Dynamin
is a GTPase enzyme required for endocytosis of activated growth factor receptors. An interaction between these proteins has
not been demonstrated in vivo. Here, we report that dynamin associates with PI 3-kinase in hematopoietic cells. We detected
both p85 and PI 3-kinase activity in dynamin immune complexes from IL-3-dependent BaF3 cells. However, this association
was significantly reduced in BaF3 cells transformed with the BCR/abl oncogene. After transformation only a 4-fold increase
in PI 3-kinase activity was detected in dynamin immune complexes, whereas grb2 associated activity was elevated 20-fold.
Furthermore, dynamin inhibited the activity of both purified recombinant and immunoprecipitated PI 3-kinase. In BaF3
cells expressing a temperature-sensitive mutant of BCR/abl, a significant decrease in p85 and dynamin association was
observed 4 h after the induction of BCR/abl activity. In contrast, in IL-3-stimulated parental BaF3 cells, this association was
increased. Our results demonstrate an in vivo association of PI 3-kinase with dynamin and this interaction regulates the
activity of PI 3-kinase. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
PI 3-kinase is a family of lipid kinases that phos-
phorylate the 3P position on the inositol ring of phos-
phatidylinositols. Type I enzymes are heterodimers
composed of 85 kDa regulatory subunits (p85) and
110 kDa catalytic subunits (p110, for a review see
[1]). PI 3-kinase and its lipid products are involved
in mitogenesis and transformation, inhibition of apo-
ptosis, regulation of the actin cytoskeleton, and in-
tracellular vesicle tra⁄cking [1^5]. PI 3-kinase is in-
active in quiescent cells and is activated by growth
factor stimulation or upon cellular transformation
and mutant forms derived from either subunit of
the kinase can transform cells [1,6^9]. PI 3-kinase
activity is required for proliferation of BCR/abl-
transformed cells, yet it is not always required for
cell growth after mitogenic stimulation by cytokines
[10^14]. The BCR/abl oncogene encodes a chimeric
protein (p210) involved in lymphoid and myeloid
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leukemias in mice and humans and which can trans-
form immature hematopoietic cells in vitro [15^17].
In tissue culture, expression of BCR/abl converts in-
terleukin-3 (IL-3)-dependent cell lines to factor-inde-
pendent growth.
The SH3 domain of PI 3-kinase associates with
dynamin in vitro, but an interaction has not been
detected in vivo [18]. Dynamin is a GTP-binding
protein required at a stage in endocytosis immedi-
ately prior to vesicle budding into the cell [19,20].
Temperature-sensitive mutations in dynamin from a
Drosophila strain called shibire are defective in endo-
cytosis [21] and point mutations in the GTP-binding
domain of human dynamin block receptor-mediated
endocytosis when expressed in mammalian cells [22].
The GTPase activity of dynamin is required for en-
docytosis [22] and for phospholipid vesiculation in
vitro [23]. A variety of factors in vitro stimulate dy-
namin’s GTPase activity, including binding to micro-
tubules, phospholipids [20] and interaction with SH3
domains in several cell signaling proteins through
distinct proline-rich sequence motifs in its C-termi-
nus [24,25]. The p85 SH3 domain weakly stimulates
dynamin GTPase activity and synergizes with acidic
phospholipids to greatly elevate GTPase activity in
vitro [26].
There may be a link between dynamin and PI
3-kinase in endocytosis and cellular proliferation.
Dynamin was initially suggested to be indirectly in-
volved in intracellular signaling events leading to cel-
lular proliferation, since phosphorylation of p85 and
PI 3-kinase activity are signi¢cantly reduced in endo-
cytosis-defective cells, which contain point mutations
in dynamin [27,28]. Subsequently, dynamin was
found to be directly involved in mitogenic signaling
to MAP kinases in a number of cells since some
receptors that do not require dynamin for internal-
ization require dynamin for mitogenic signaling
[29,30]. Another GTP binding protein, ras, binds PI
3-kinase speci¢cally in a GTP-dependent manner and
stimulates its activity [31]. This interaction occurs via
direct association with p110.
Our aims were to determine if the interaction be-
tween dynamin and PI 3-kinase occurs in cells and
whether it might regulate PI 3-kinase activity. Such
an interaction may be associated with receptor-medi-
ated endocytosis or cellular transformation. We re-
port that dynamin associates with PI 3-kinase in
hematopoietic cells and inhibits its lipid kinase activ-
ity. Mitogenic stimulation increases their association,
but cellular transformation leads to a loss of associ-
ation.
2. Materials and methods
2.1. Cell lines and cell culture
BaF3 is an IL-3-dependent pro-B lymphocytic
murine cell line, BaFp210 is a stably transfected
cell line which expresses p210 BCR/abl oncoprotein
[17] and BaF-ts-p210 cells express a temperature-sen-
sitive p210 BCR/abl mutant which becomes active
when cells are shifted from a non-permissive (39‡C)
to a permissive (33‡C) temperature [14,32]. Hemato-
poietic cells were grown in suspension culture in
RPMI 1640 medium containing 10% fetal calf serum.
BaF3 cells had an additional 10% WEHI-condi-
tioned medium as the source of IL-3. Cells were
brought to quiescence by incubating in RPMI me-
dium containing 0.5% fetal calf serum (and 0.1%
WEHI-conditioned medium for BaF3 cells) for 14
h. Under these conditions cell viability was over
90%, as determined by trypan blue exclusion. PC12
cells were a gift from Lewis C. Cantley (Beth Israel
Hospital, Boston, MA) and were grown on collagen-
coated tissue culture dishes in DMEM medium sup-
plemented with 10% fetal calf serum and 5% horse
serum. PC12 cells were di¡erentiated with 50 WM
nerve growth factor in medium containing 0.5% fetal
calf serum and 0.5% horse serum for 4 days.
2.2. Preparation of cell lysates
Cells were collected by centrifugation and washed
twice with phosphate-bu¡ered saline (PBS). 2U107
cells were suspended in 1 ml of lysis bu¡er (50 mM
Hepes (pH 7.5) 10% glycerol, 1% Nonidet-P40, 0.5
mM EDTA, 5 mM Na3VO4, 10 Wg/ml leupeptin and
aprotinin, 5 Wg/ml pepstatin and 0.5 mM phenyl-
methylsulfonyl£uoride). After incubating on ice for
10 min, the lysates were centrifuged at 12 000Ug for
10 min and the supernatant was used as the whole
cell lysate (WCL).
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2.3. Puri¢cation of enzymes
Puri¢ed active PI 3-kinase was a generous gift
from Andrea Massachio and Stephen Harrison (Har-
vard Medical School, Boston, MA). Brie£y, p85 and
p110 subunits were co-expressed as GST-fusion pro-
teins in SF9 cells. PI 3-kinase was puri¢ed to near
homogeneity by glutathione^agarose followed by
cleavage with trypsin and gel ¢ltration chromatogra-
phy on a Superdex 200 column. Dynamin puri¢ca-
tion from sheep brain was as described [33], with
minor modi¢cations to the puri¢cation to remove
the detergent which interferes with the PI 3-kinase
assay. The detergent Tween-80 was omitted from
the S-Sepharose column step and the elution of dy-
namin from phenyl^Sepharose column was achieved
by elevated pH (pH 9.7 in Tris^HCl, rather than 1%
Tween-80), followed by pH neutralization to 7.4 with
HCl. This change in the puri¢cation method did not
alter the maximal dynamin GTPase activity stimu-
lated by phospholipids and yielded dynamin at 0.04
mg/ml.
2.4. Antibodies and Immunoprecipitation
Monoclonal and polyclonal anti-p85, monoclonal
anti-grb2 and monoclonal anti-phosphotyrosine anti-
body 4G10 were purchased from UBI (New York,
USA). Dynamin antibody was produced as described
[33]. Whole cell lysates were incubated with appro-
priate antibodies as shown in the ¢gure legends for
2 h at 4‡C. Then 40 Wl of a 50% suspension of pro-
tein A- or protein G-Sepharose (Sigma) was added
for another 60 min. Immune complexes were washed
sequentially with PBS, TNE (10 mM Tris^HCl (pH
7.4), 100 mM NaCl, 1 mM EDTA) and PBS. The
washed beads were either resuspended in sodium do-
decyl sulfate (SDS) sample bu¡er, denatured at 85‡C
for 4 min and analyzed by SDS^polyacrylamide gel
electrophoresis (PAGE), or were used directly for the
PI 3-kinase assay.
2.5. Western blotting
Proteins resolved by SDS^PAGE in mini-gels [34]
were transferred to nitrocellulose membrane (Phar-
macia, Wisconsin) using a mini trans-blot apparatus
(Bio-Rad, California). The membranes were blocked
in 10% non-fat milk for 1 h and probed with anti-
bodies as indicated in the legends to the ¢gures. Im-
munoreactive bands were visualized by enhanced
chemiluminescence (ECL) according to the manufac-
turer’s instructions (Amersham, Illinois).
2.6. PI 3-kinase assays
The protein complexes on protein A-Sepharose
beads were sequentially washed with lysis bu¡er (50
mM Hepes (pH 7.5), 10% glycerol, 1% Nonidet-P40,
0.5 mM EDTA, 5 mM Na3VO4), PBS, TNE (see
above) and PI 3-kinase activity was assayed as pre-
viously described [35]. In WCL total PI 3-kinase ac-
tivity was determined after 1000-fold dilution to de-
crease the detergent as described [35]. For puri¢ed
recombinant PI 3-kinase, 250 ng of p85/p110 was
assayed with increasing concentrations of dynamin
or guanine nucleotides.
3. Results
Although the SH3 domain of p85 binds dynamin
in vitro, an association was not detected in intact
PC12 cells [18,24]. To determine whether dynamin
associates with PI 3-kinase in hematopoietic cells,
dynamin was immunoprecipitated from parental
and BCR/abl-transformed BaF3 cells and the im-
mune complexes were probed with anti-p85 antibod-
ies. Dynamin constitutively associated with p85 in
quiescent BaF3 cells (Fig. 1A, lane 1). In BCR/abl-
transformed BaF3 cells, BaFp210, the association
was reduced by 80% (lane 2). Dynamin was ex-
pressed at equal levels in parental and transformed
cells (Fig. 1B, lanes 1 and 2) and a constant amount
of dynamin was immunoprecipitated from both cell
lines (Fig. 1B, lanes 5 and 6). Similarly, the expres-
sion of p85 and Grb2 proteins did not change in
these cells upon transformation (data not shown,
see also [14,35]). Therefore, dynamin exists as a com-
plex with p85 in quiescent BaF3 cells and this com-
plex is disrupted in BCR/abl-transformed cells. As
previously reported [18], we also did not detect an
association of dynamin with p85 in non-di¡erenti-
ated and NGF-di¡erentiated PC12 cells (data not
shown). However, we observed a constitutive associ-
ation of PI 3-kinase with dynamin in rat brain nerve
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terminals (P.J.R., D.H.F. and C.S.M., data not
shown), suggesting that their association is not re-
stricted to hematopoietic cells.
Dynamin I, the neuronal form of dynamin is
highly homologous to dynamin II, which is ubiqui-
tously expressed [36,37]. In this study, we have used
antibodies to dynamin I, which weakly cross-react
with dynamin II. The antibodies recognize the dyna-
min isoforms present in murine hematopoietic cells
detected by Western blotting and immunoprecipita-
tion. Furthermore, dynamin from PC12 cells, which
express both dynamin I and II isoforms [36], had the
same mobility on SDS^PAGE as dynamin from pa-
rental and transformed BaF3 cells (Fig. 1B).
Cell transformation by BCR/abl increases tyrosine
phosphorylation of proteins, which leads to SH2 do-
main-mediated interactions and activation of PI
3-kinase [13,14]. In contrast to a report which uses
cells overexpressing dynamin [38], we found that
dynamin was not phosphorylated on tyrosine and
did not associate with any tyrosine-phosphorylated
proteins in either parental or BCR/abl-transformed
cells (Fig. 1C).
We next examined whether dynamin immune com-
plexes also contained the catalytic subunit of PI
3-kinase (p110). BCR/abl transformation activates
PI 3-kinase and the transforming activity of the
BCR/abl oncogene requires PI 3-kinase activity
[10,14]. As we previously reported [11,14], transfor-
mation produced a 20-fold increase in PI 3-kinase
activity in immune complexes obtained by immuno-
precipitation of Grb2 or phosphotyrosine (Fig. 2). In
contrast, dynamin immune complexes from BaFp210
Fig. 1. Association of dynamin with p85 in intact cells. (A) Dy-
namin associates with p85. Dynamin was immunoprecipitated
with polyclonal anti-dynamin antibodies from lysates (6 mg
protein) of BaF3 (lane 1), BaFp210 (lane 2) cells or from lysis
bu¡er only (lane 3), samples run on SDS gels and transferred
to nitrocellulose. The nitrocellulose was probed with a mono-
clonal anti-p85 antibody (UBI, New York) and immunoreactive
bands were detected by ECL. All results are representative of
at least three independent experiments. (B) Dynamin levels are
unaltered by transformation. Whole cell lysate (WCL) proteins
(100 Wg) from BaF3 (lane 1), BaFp210 (lane 2) cells and WCL
protein (50 Wg) from PC12 (lane 3) cells were probed for the
expression of dynamin. Dynamin was immunoprecipitated with
polyclonal anti-dynamin antibodies from PC12 cell lysates (lane
4) containing 1 mg protein, and from BaF3 (lane 5) and
BaFp210 (lane 6) cell lysates containing 3 mg of protein. The
samples were separated by SDS^PAGE, transferred to nitrocel-
lulose and probed with anti-dynamin antibodies and HRP-con-
jugated secondary antibodies. The arrow shows the migration
of dynamin at 96 kDa. (C) Dynamin does not associate with
proteins phosphorylated on tyrosine. WCL protein (100 Wg)
from BaFp210 cells (lane 1) as a control and 2 mg protein
from BaF3 (lane 2) or BaFp210 (lane 3) cell lysates, immuno-
precipitated with polyclonal anti-dynamin antibodies were ana-
lyzed on an SDS^polyacrylamide gel and transferred to nitro-
cellulose. Tyrosine-phosphorylated proteins were detected with
monoclonal anti-phosphotyrosine antibodies and HRP-conju-
gated secondary antibodies. As a control for the immunoprecip-
itation, lysis bu¡er without cells was incubated with anti-dyna-
min antibodies (lane 4). The immunoreactive bands were




D. Harrison-Findik et al. / Biochimica et Biophysica Acta 1538 (2001) 10^19 13
cells contained only a 4-fold increase (Fig. 2).
Although relatively lower PI 3-kinase activity was
detected, this result also indicates that the catalytic
subunit is present in the dynamin immune com-
plexes. It is also important to note that the lower
level of PI 3-kinase activity in dynamin immune com-
plexes correlates with the reduced association ob-
served between dynamin and p85 in BCR/abl-trans-
formed cells. However, it is also possible that
dynamin might suppress activity of the PI 3-kinase
catalytic subunit.
To determine whether dynamin might regulate PI
3-kinase activity, we studied the e¡ect of puri¢ed
dynamin on PI 3-kinase activity. Dynamin I was pu-
ri¢ed from ovine brain by a method modi¢ed to
obtain detergent-free product which has high phos-
pholipid-stimulated GTPase activity. Addition of pu-
ri¢ed dynamin I to whole cell lysates from trans-
formed BaFp210 cells inhibited total PI 3-kinase
activity in a concentration-dependent manner (Fig.
3A). This suggests that dynamin I blocks most iso-
forms of PI 3-kinase, even under conditions where PI
3-kinase is maximally stimulated by expression of
BCR/abl and is associated with other proteins such
as Grb2. Puri¢ed dynamin I also inhibited the activ-
ity of puri¢ed recombinant PI 3-kinase (Fig. 3B).
Therefore, our results strongly suggest that dynamin
I directly inhibits the generation of PI 3-kinase lipid
products.
GTP-bound, but not GDP-bound ras stimulates
PI 3-kinase activity [31]. Since dynamin is also a
guanine nucleotide-binding protein, we tested
whether nucleotide hydrolysis (GTP) or nucleotide
binding (GDP or GTP-Q-S) to dynamin alters its ef-
fect on PI 3-kinase activity. Guanine nucleotide bind-
ing signi¢cantly increased its inhibitory action on
puri¢ed PI 3-kinase (Fig. 4A). However, guanine nu-
cleotides themselves had no e¡ect on PI 3-kinase
activity in whole cell lysates (Fig. 4B). Together,
these results strongly suggest that dynamin associates
with PI 3-kinase, which in turn leads to the inhibition
of PI 3-kinase activity. Furthermore, guanine nucle-
Fig. 3. Puri¢ed dynamin I inhibits the activity of PI 3-kinase.
(A) Whole cell lysate proteins from BaFp210 cells (40 ng) were
assayed in the absence or presence of di¡erent concentrations
of puri¢ed dynamin for PI 3-kinase activity. PI 3-kinase activity
was determined by formation of PIP3. (B) Puri¢ed recombinant
PI 3-kinase was incubated with the indicated amounts of puri-
¢ed dynamin I and assayed for PI 3-kinase activity. The results
are the mean ( þ S.E.M.) of three independent experiments.
Fig. 2. PI 3-kinase activity in dynamin, Grb2 and phosphotyro-
sine immune complexes. Whole cell lysate protein from BaF3
(solid bars) or BaFp210 (open bars) cells (4.5 mg) was immuno-
precipitated with normal rabbit serum (NRS) as a control or
with anti-grb2, anti-dynamin or anti-phosphotyrosine antibod-
ies. PI 3-kinase activity in the immune complexes was deter-
mined by formation of PIP3. PI 3-kinase activity in parental
BaF3 cells was expressed as 100% for each of the antibodies
shown, and the activity in transformed cells was then expressed
as a fold increase. The results are the mean ( þ S.D.) of three
independent experiments.
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otide binding to dynamin, rather than GTP hydroly-
sis, potentiates this inhibitory action.
We next asked whether inhibition of PI3-kinase
occurs in intact cells. Dynamin immune complexes
from BCR/abl-transformed cells were treated with
guanine nucleotides. GDP, GTP or GTP-Q-S treat-
ment reduced PI 3-kinase activity in dynamin im-
mune complexes by 40^60% (Fig. 5A). Inhibition of
PI 3-kinase activity in dynamin immune complexes
was speci¢c for dynamin because treatment of phos-
photyrosine immune complexes (which do not con-
tain dynamin) with guanine nucleotides had no sig-
ni¢cant e¡ect on PI 3-kinase activity (Fig. 5B).
To understand the functional context for the reg-
ulation of PI 3-kinase activity by dynamin further,
we compared their interaction in endocytosis (for
dynamin) versus cellular transformation (for PI 3-ki-
nase). We took advantage of the fact that untrans-
formed BaF3 cells require binding of the cytokine
IL-3 to its receptor for cellular growth, which acti-
vates receptor-mediated endocytosis. However, BCR/
Fig. 5. Inhibition of PI 3-kinase activity in dynamin immune
complexes. (A) Cell lysates (5 mg) from BaFp210 cells were im-
munoprecipitated with polyclonal anti-dynamin antibodies. (B)
Cell lysates from BaFp210 cells (2 mg) were immunoprecipi-
tated with anti-phosphotyrosine antibodies. Immune complexes
were washed and preincubated with control bu¡er or with
GDP (2 mM), GTP (2 mM) or GTP-Q-S (5 WM) for 2 min.
Following the preincubation, the samples in both panels were
directly assayed for PI 3-kinase activity. In all panels the PI
3-kinase activity in control immune complexes was expressed as
100% and results are the mean ( þ S.E.M.) of four independent
experiments.
Fig. 4. Guanine nucleotides enhance the inhibition of PI 3-ki-
nase by dynamin. (A) Puri¢ed dynamin (7.4 ng) was preincu-
bated for 2 min with GDP (2 mM), GTP (2 mM) or GTP-Q-S
(10 WM) and added to puri¢ed PI 3-kinase. PI 3-kinase activity
was determined in three independent experiments and the re-
sults expressed as percent of control activity (mean þ S.D.). Val-
ues for GDP and GTP were signi¢cantly di¡erent from control
in the presence of dynamin (Student’s one-tailed t-test,
P6 0.05). (B) WCL proteins (40 ng) from BaFp210 cells were
incubated with 1 mM GTP, 1 mM GDP or 5 WM GTP-Q-S for
2 min. The samples were then assayed for PI 3-kinase. The ¢nal
detergent (Triton X-100) concentration in the assay was
0.001%.
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abl-transformed cells do not require IL-3 for growth.
We therefore conducted two series of experiments to
distinguish between endocytosis and cellular trans-
formation. In the ¢rst series, we investigated the as-
sociation of dynamin with p85 in receptor-mediated
endocytosis by stimulating BaF3 cells with IL-3. Cy-
tokine stimulation increased dynamin’s association
with p85 in BaF3 cells (Fig. 6, lanes 1^3). In the
second series, we examined whether the association
of dynamin with p85 is altered by oncogenic trans-
formation in the absence of changes in receptor-
mediated endocytosis. For this, we employed the
BaF-ts-p210 cells, which express a temperature-sensi-
tive (ts) p210 BCR/abl tyrosine kinase mutant. At the
non-permissive temperature (39‡C), these cells re-
quire IL-3 for growth and have greatly reduced
BCR/abl kinase activity. When the cells are shifted
to a permissive temperature (33‡C) this leads to the
activation of abl tyrosine kinase and the cells start to
proliferate in the absence of IL-3 [14,32]. Within 4 h
after the shift to the permissive 33‡C the association
between p85 and dynamin decreased (Fig. 6, lanes 4
and 5). The presence or absence of IL-3 had no e¡ect
on the amount of p85 complexed with dynamin in
BaF-ts-p210 cells (data not shown). These results re-
veal that an increased association of dynamin with
PI 3-kinase correlates with internalization of growth
factor receptors, while a decreased association corre-
lates with BCR/abl-induced transformation.
4. Discussion
Previous studies revealed that the SH3 domain of
p85 stimulates dynamin GTPase activity synergisti-
cally with phospholipids [24,26]. Dynamin-defective
cells demonstrate reduced p85 phosphorylation [27]
and reduced PI 3-kinase activity [28], suggesting that
the two enzymes might share a common signaling
pathway. The aims of this study were to determine
whether these proteins interact in intact cells and the
consequences of their interaction on PI 3-kinase ac-
tivity. Our two key ¢ndings were that the two pro-
teins exhibit an association in murine hematopoietic
cells and that dynamin I directly inhibits PI 3-kinase
activity.
We provide the ¢rst evidence for an association
between dynamin and PI 3-kinase which includes
both subunits of PI 3-kinase. In contrast to a pre-
vious study [18], we detected a constitutive interac-
tion of dynamin with p85 in murine hematopoietic
BaF3 cells and this constitutive association was in-
creased upon stimulation with IL-3. Dynamin is in-
volved in protein^protein interactions with other sig-
naling proteins via SH3 domain interactions with its
proline-rich tail or via interactions with its PH do-
main [18,24^26,38^45]. A limited number of these in
vitro interactions occur in vivo, including binding of
Grb2, amphiphysin, PLCQ and src to dynamin’s pro-
line-rich tail and binding of LQ subunits of heterotri-
meric G proteins to the PH domain. In most cases
dynamin does not exist as a preformed complex in
cells with these proteins, except for Grb2 [41], but
forms a complex upon stimulation. There are many
reports of receptor activation recruiting dynamin or
altering its interaction with other signaling proteins
[18,27,38,39,41,46^48]. Among these interactions,
only that between dynamin and the SH3 domain of
amphiphysin is required for receptor-mediated endo-
cytosis [43,45]. However, our results in hematopoietic
cells suggest that this recruitment of dynamin occurs
for the dual purpose of initiating endocytosis and
Fig. 6. Growth factors and transformation e¡ects on dynamin
and PI 3-kinase association. Quiescent parental BaF3 cells (lane
1) were stimulated with 10% fetal calf serum (FCS, lane 2) or
IL-3 (10% WEHI-conditioned medium, lane 3) for 10 min.
Temperature-sensitive BaF-ts-p210 cells were grown at non-per-
missive 39‡C and shifted to the permissive 33‡C for 4 h to in-
duce BCR/abl tyrosine kinase activity (lanes 4,5). Cell lysates
from all cells were prepared and were immunoprecipitated with
anti-dynamin antibodies, and immune complexes were isolated
with protein A^Sepharose. The samples were resolved on SDS^
polyacrylamide gels, transferred to nitrocellulose, probed with
monoclonal anti-p85 antibodies and HRP-conjugated secondary
antibodies, and immunoreactive bands were detected by ECL.
The position of p85 is indicated with an arrow. Results are rep-
resentative of three independent experiments.
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also inhibiting PI 3-kinase activation. Furthermore,
this association at the plasma membrane might en-
hance the GTPase activity of dynamin.
Inhibition of PI 3-kinase by dynamin was detected
in two ways. Firstly, the addition of puri¢ed dyna-
min to whole cell lysates resulted in inhibition of
total PI 3-kinase activity. Secondly, a direct e¡ect
was demonstrated by inhibition of recombinant pu-
ri¢ed Type IA PI 3-kinase (p85/p110 heterodimer) by
puri¢ed dynamin I. This is the ¢rst demonstration
that dynamin directly regulates the activity of other
enzymes involved in intracellular signaling. Previous
studies have revealed several other mechanisms of
inhibition of PI 3-kinase [49^52]. The 14-3-3 protein
may act as an inhibitor of the p110 subunit when
overexpressed in Jurkat cells [52] and reduces insulin
receptor signaling to PI 3-kinase via IRS1 [53]. The
p110 subunit possesses a serine/threonine autokinase
activity that phosphorylates p85 on serine residues
and reduces PI 3-kinase activity [49,54]. Thrombin-
induced activation of PI 3-kinase in platelets Q-p110,
(Type IB) is inhibited by the LQ subunit of G proteins
and/or by ADP ribosylation of the small G protein
Rho [51]. These studies suggest that regulation of
Type I PI 3-kinase is possible through either p85 or
p110 subunits. Here we demonstrate that dynamin is
another negative regulator of PI 3-kinase activity.
Furthermore, the potency of dynamin was increased
by guanine nucleotide binding. Similarly, GTP-
bound ras, but not GDP-bound ras, stimulates PI
3-kinase activity by direct association with p110
rather than with p85 [31], but the mechanism of in-
hibition of PI 3-kinase by dynamin is not yet known.
Mutual regulation of dynamin and PI 3-kinase may
be critical for local events during signal transduction
following growth factor receptor activation in cells.
Endocytosis of growth factor receptors regulates
subsequent intracellular signaling pathways initiated
by the receptors [27,28]. Expression of a K44A or
K44E dominant-negative GTPase mutant of dyna-
min blocks receptor-mediated endocytosis and at-
tenuates growth factor receptor coupling to MAP
kinase activation [27,28,55]. Dynamin-defective cells
also have altered signaling through PI 3-kinase [27]
and with approximately 50% decrease in insulin-
stimulated activation of the PI 3-kinase associated
with IRS1 [28]. These studies are consistent with
our ¢ndings that dynamin is involved in the regula-
tion of PI 3-kinase activity in intact cells. A unifying
hypothesis in the context of our data is that the
complex of dynamin and PI 3-kinase formed upon
stimulation of hematopoietic cells with growth fac-
tors recruits dynamin for early stages of endocytosis
and limits further formation of PI 3-kinase lipid
products, which might be essential for the initiation
of endocytosis at the plasma membrane.
We found that transformation of BaF3 cells by
BCR/abl oncogene is accompanied by a decreased
association of dynamin and PI 3-kinase. PI 3-kinase
activation is required for proliferation of BCR/abl-
transformed hematopoietic cells [56]. The dissocia-
tion of the dynamin and PI 3-kinase complex in
transformed cells was not likely to be due to altered
receptor-mediated endocytosis since no extracellular
growth factor was required. Experiments with tem-
perature-sensitive BCR/abl mutants also showed that
the decreased association occurred within 4 h of in-
duction of BCR/abl tyrosine kinase activity and IL-3
did not in£uence the decreased association. In BCR/
abl-transformed cells, PI 3-kinase also associates
with Grb2, Shc, Cbl and p62 [13,14,57,58], which
increase PI 3-kinase activity. BCR/abl transforma-
tion might replace the constitutive dynamin- PI
3-kinase complex with higher a⁄nity complexes
such as Grb2 and PI 3-kinase, resulting in the acti-
vation of PI 3-kinase. However, dynamin is now
known to play a direct role in mitogenic signal trans-
duction in the absence of detectable endocytosis
[29,59^61]. Dynamin is directly involved in signaling
to MAP kinase, even in the absence of endocytosis.
Our observations that dynamin interacts with PI
3-kinase in the absence of endocytosis suggests that
this interaction may be an important part of mito-
genic signaling in hematopoietic cells.
Therefore, dynamin associates with the SH3 do-
main of PI 3-kinase in vitro and with PI 3-kinase
in hematopoietic cells. While dynamin is stimulated
by p85, PI 3-kinase activity, in turn, is inhibited by
dynamin. The association of dynamin with PI 3-ki-
nase in hematopoietic cells might be regulated in
opposite directions by either proliferative signals or
by cellular transformation. Our results suggest a hy-
pothesis that mitogenic stimulation with IL-3 recruits
PI 3-kinase to dynamin at the plasma membrane to
locally block PI 3-kinase activity, while possibly en-
hancing the GTPase activity of dynamin. In addi-
BBAMCR 14714 22-1-01
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tion, dynamin may be indirectly involved in the reg-
ulation of cellular transformation through the release
of PI 3-kinase inhibition, as detected in cells trans-
formed by BCR/abl.
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